Mycobacterium Kansasii Differential Diagnoses

1. Taillard C, Greub G, Weber R, Pfyffer GE, Bodmer T, Zimmerli S, et al. Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey. J Clin Microbiol. 2003 Mar. 41 (3):1240-4. [QxMD MEDLINE Link].

2. Park HK, Koh WJ, Shim TS, Kwon OJ. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea. Yonsei Med J. 2010 Jul. 51(4):552-6. [QxMD MEDLINE Link]. [Full Text].

3. Han SH, Kim KM, Chin BS, Choi SH, Lee HS, Kim MS, et al. Disseminated Mycobacterium kansasii infection associated with skin lesions: a case report and comprehensive review of the literature. J Korean Med Sci. 2010 Feb. 25(2):304-8. [QxMD MEDLINE Link]. [Full Text].

4. Bloch KC, Zwerling L, Pletcher MJ. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med. 1998 Nov 1. 129(9):698-704. [QxMD MEDLINE Link].

5. Sheu LC, Tran TM, Jarlsberg LG, Marras TK, Daley CL, Nahid P. Nontuberculous mycobacterial infections at San Francisco General Hospital. Clin Respir J. 2014 May 6. [QxMD MEDLINE Link].

6. Spaulding AB, Lai YL, Zelazny AM, Olivier KN, Kadri SS, Prevots DR, et al. Geographic Distribution of Nontuberculous Mycobacterial Species Identified among Clinical Isolates in the United States, 2009-2013. Ann Am Thorac Soc. 2017 Nov. 14 (11):1655-1661. [QxMD MEDLINE Link].

7. Corbett EL, Churchyard GJ, Hay M. The impact of HIV infection on Mycobacterium kansasii disease in South African gold miners. Am J Respir Crit Care Med. 1999 Jul. 160(1):10-4. [QxMD MEDLINE Link].

8. Evans AJ, Crisp AJ, Hubbard RB. Pulmonary Mycobacterium kansasii infection: comparison of radiological appearances with pulmonary tuberculosis. Thorax. 1996 Dec. 51(12):1243-7. [QxMD MEDLINE Link].

9. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013 Dec. 42(6):1604-13. [QxMD MEDLINE Link].

10. Okoi C, Anderson STB, Antonio M, Mulwa SN, Gehre F, Adetifa IMO. Non-tuberculous Mycobacteria isolated from Pulmonary samples in sub-Saharan Africa - A Systematic Review and Meta Analyses. Sci Rep. 2017 Sep 20. 7 (1):12002. [QxMD MEDLINE Link].

11. Maliwan N, Zvetina JR. Clinical features and follow up of 302 patients with Mycobacterium kansasii pulmonary infection: a 50 year experience. Postgrad Med J. 2005. 81:530-33. [QxMD MEDLINE Link].

12. Marras TK, Campitelli MA, Lu H, Chung H, Brode SK, Marchand-Austin A, et al. Pulmonary Nontuberculous Mycobacteria-Associated Deaths, Ontario, Canada, 2001-2013. Emerg Infect Dis. 2017 Mar. 23 (3):468-476. [QxMD MEDLINE Link].

13. Marras TK, Morris A, Gonzalez LC. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med. 2004. 170:793-98. [QxMD MEDLINE Link].

14. Mitha M, Naicker P, Taljaard J. Cutaneous Mycobacterium kansasii infection in a patient with AIDS post initiation of antiretroviral therapy. J Infect Dev Ctries. 2011 Jul 27. 5(7):553-5. [QxMD MEDLINE Link].

15. Evans SA, Colville A, Evans AJ. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis. Thorax. 1996 Dec. 51(12):1248-52. [QxMD MEDLINE Link].

16. Witzig RS, Fazal BA, Mera RM. Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Clin Infect Dis. 1995 Jul. 21(1):77-85. [QxMD MEDLINE Link].

17. Bakuła Z, Kościuch J, Safianowska A, Proboszcz M, Bielecki J, van Ingen J, et al. Clinical, radiological and molecular features of Mycobacterium kansasii pulmonary disease. Respir Med. 2018 Jun. 139:91-100. [QxMD MEDLINE Link].

18. Gail L. Woods, M.D. et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard. Second Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. M24A2:

19. Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis. 2000. 31:1209-1. [QxMD MEDLINE Link].

20. Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012 Jul. 25 (3):545-82. [QxMD MEDLINE Link].

21. Smith MB, Molina CP, Schnadig VJ. Pathologic features of Mycobacterium kansasii infection in patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med. 2003. 127:554-60. [QxMD MEDLINE Link].

22. Griffith DE. Management of disease due to Mycobacterium kansasii. Clin Chest Med. 2002. 23:613-21. [QxMD MEDLINE Link].

23. Hombach M, Somoskövi A, Hömke R, Ritter C, Böttger EC. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST. Int J Med Microbiol. 2013 Jul. 303(5):270-6. [QxMD MEDLINE Link].

24. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15. 175(4):367-416. [QxMD MEDLINE Link].

25. Wu TS, Leu HS, Chiu CH, Lee MH, Chiang PC, Wu TL, et al. Clinical manifestations, antibiotic susceptibility and molecular analysis of Mycobacterium kansasii isolates from a university hospital in Taiwan. J Antimicrob Chemother. 2009 Sep. 64(3):511-4. [QxMD MEDLINE Link].

26. [Guideline] Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017 Nov. 72 (Suppl 2):ii1-ii64. [QxMD MEDLINE Link].

27. Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012 Jul. 25(3):545-82. [QxMD MEDLINE Link]. [Full Text].

28. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. 1997 Aug. 156(2 Pt 2):S1-25. [QxMD MEDLINE Link].

29. Guna R, Munoz C, Dominguez V. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother. 2005. 55:950-53. [QxMD MEDLINE Link].

30. DeStefano MS, Shoen CM, Cynamon MH. Therapy for Mycobacterium kansasii Infection: Beyond 2018. Front Microbiol. 2018. 9:2271. [QxMD MEDLINE Link].

31. Alcaide F, Benitez MA, Martin R. Epidemiology of Mycobacterium kansasii. Ann Intern Med. 1999 Aug 17. 131(4):310-1. [QxMD MEDLINE Link].

32. Breathnach A, Levell N, Munro C. Cutaneous Mycobacterium kansasii infection: case report and review. Clin Infect Dis. 1995 Apr. 20(4):812-7. [QxMD MEDLINE Link].

33. Davidson PT. The diagnosis and management of disease caused by M. avium complex, M. kansasii, and other mycobacteria. Clin Chest Med. 1989 Sep. 10(3):431-43. [QxMD MEDLINE Link].

34. Fishman JE, Schwartz DS, Sais GJ. Mycobacterium kansasii pulmonary infection in patients with AIDS: spectrum of chest radiographic findings. Radiology. 1997 Jul. 204(1):171-5. [QxMD MEDLINE Link].

35. O'Brien RJ. The epidemiology of nontuberculous mycobacterial disease. Clin Chest Med. 1989 Sep. 10(3):407-18. [QxMD MEDLINE Link].

36. Wolinsky E. Mycobacterial diseases other than tuberculosis. Clin Infect Dis. 1992 Jul. 15(1):1-10. [QxMD MEDLINE Link].

37. Woods GL, Meyers WM. Mycobacterial Diseases. Damjanov I, Linder J, eds. Anderson's Pathology. St. Louis, Mo: Mosby; 1996. Vol 10: 843-55.

Janak Koirala, MD, MPH, FACP, FIDSA Professor Emeritus, Division of Infectious Diseases, Department of Internal Medicine, Southern Illinois University School of Medicine

Janak Koirala, MD, MPH, FACP, FIDSA is a member of the following medical societies: American College of Physicians, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, HIV Medicine Association, Infectious Diseases Society of America, International Society for Infectious Diseases, Nepal Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Aaron Glatt, MD Chairman, Department of Medicine, Chief, Division of Infectious Diseases, Hospital Epidemiologist, South Nassau Communities Hospital

Aaron Glatt, MD is a member of the following medical societies: American Association for Physician Leadership, American College of Chest Physicians, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Infectious Diseases Society of America, International AIDS Society, Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Klaus-Dieter Lessnau, MD, FCCP Former Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory, Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article